Bactiguard has been informed that the European Patent Office (EPO) intends to grant a European patent for Bactiguard’s infection prevention technology. The new patent, which is the third generation, will provide extensive worldwide protection for the Bactiguard technology until 2039.
For more than 30 years Bactiguard’s technology, based on a thin noble metal alloy coating, has been developed and applied to medical devices for both short- and long-term use. In 2019, Bactiguard initiated a global partnership with Zimmer Biomet, and in 2021, ZNN Bactiguard orthopedic trauma implants were launched. In 2022, the Zimmer Biomet partnership was expanded to cover most of their product portfolio.
The Bactiguard technology can be used in most areas where there is a need for infection prevention and tissue-friendly properties and is based on a well-kept trade secret. It is also protected by patents. The current patent, the second generation, is in force in the USA until 2027 and until 2029 in other countries. The application for the third generation of patents was submitted in 2019 and the EPO has now confirmed that they intend to grant a European patent, valid until 2039.
“We are very pleased that the EPO has confirmed that the new generation of patents will be granted. This will further strengthen and extend the worldwide protection for the versatile Bactiguard technology and make it even more attractive for existing and new license partners,” said Anders Göransson, CEO.
Bactiguard has been informed that the European Patent Office (EPO) intends to grant a European patent for Bactiguard’s infection prevention technology. The new patent, which is the third generation, will provide extensive worldwide protection for the Bactiguard technology until 2039.
For more than 30 years Bactiguard’s technology, based on a...
Bactiguard has been informed that the European Patent Office (EPO) intends to grant a European patent for Bactiguard’s infection prevention technology. The new patent, which is the third generation, will provide extensive worldwide protection for the Bactiguard technology until 2039.
For more than 30 years Bactiguard’s technology, based on a thin noble metal alloy coating, has been developed and applied to medical devices for both short- and long-term use. In 2019, Bactiguard initiated a global partnership with Zimmer Biomet, and in 2021, ZNN Bactiguard orthopedic trauma implants were launched. In 2022, the Zimmer Biomet partnership was expanded to cover most of their product portfolio.
The Bactiguard technology can be used in most areas where there is a need for infection prevention and tissue-friendly properties and is based on a well-kept trade secret. It is also protected by patents. The current patent, the second generation, is in force in the USA until 2027 and until 2029 in other countries. The application for the third generation of patents was submitted in 2019 and the EPO has now confirmed that they intend to grant a European patent, valid until 2039.
“We are very pleased that the EPO has confirmed that the new generation of patents will be granted. This will further strengthen and extend the worldwide protection for the versatile Bactiguard technology and make it even more attractive for existing and new license partners,” said Anders Göransson, CEO.
Copy to clipboard 
